Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Enliven Therapeutics and keeping the price target at $38.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors surrounding Enliven Therapeutics’ lead asset, ELVN-001. The drug, a BCR::ABL1 active site tyrosine kinase inhibitor, has shown promising results in treating chronic myeloid leukemia (CML) with a significant major molecular response rate in a heavily pretreated patient population. The drug’s good tolerability further strengthens its potential as a treatment option.
Additionally, Enliven’s strategic plans to initiate a pivotal study in 2026, focusing on the 2L+ setting, align with the potential of ELVN-001 to become a key option following the currently approved treatment, Scemblix. The commercial positioning of ELVN-001 as a potent and selective inhibitor suggests it could be a preferred choice among physicians, enhancing its market potential. Furthermore, the company’s financial health, with more than 3.5 years of cash runway, supports its continued development efforts, making it an attractive investment opportunity.
In another report released on October 23, Goldman Sachs also maintained a Buy rating on the stock with a $38.00 price target.